Immunosuppression in pregnancy: choices for infant and maternal health.

摘要: Successful pregnancy outcomes are possible after all types of solid organ transplantation and thousands successful pregnancies in such women have been reported. As immunosuppressive medications required to maintain adequate graft maternal survival, major concerns the effect these agents on fetus well being mother graft, against a background continuing advances modifications therapy. Women should avoid unnecessary during but clinicians worry most about teratogens; (environmental, pharmaceuticals or other chemicals) that cause abnormal development, whether this be an overt structural birth defect more subtle derangements embryonic fetal development. A concern is any agent combination condition(s) may teratogenic, risk increased transplant population. The goal immunosuppression ensure patient survival by preventing acute rejection. Combinations allow for synergistic effects while minimising drug toxicities. No specific has deemed optimal recently available combinations require further study. Although there known theoretical risks fetus, now rule recipients. This without apparent increase type incidence malformations newborns, usually with no evidence dysfunction and/or irreversible deterioration either related prepregnancy problems unpredictable gestational factors. For immunosuppression, what best her outcome and, although malformation pattern reported date, some interesting trends worthy continued analyses. balance good lowest toxicity must management.